June 15, 2020 / 7:43 PM / 23 days ago

BRIEF-Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval Of Zepzelca For Treatment Of Metastatic Small Cell Lung Cancer

June 15 (Reuters) - Jazz Pharmaceuticals PLC:

* JAZZ PHARMACEUTICALS ANNOUNCES U.S. FDA ACCELERATED APPROVAL OF ZEPZELCA™ (LURBINECTEDIN) FOR THE TREATMENT OF METASTATIC SMALL CELL LUNG CANCER

* JAZZ PHARMACEUTICALS - ZEPZELCA IS EXPECTED TO BE COMMERCIALLY AVAILABLE IN U.S. IN EARLY JULY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below